Vote Scores
Filings read through

Kalaris Therapeutics, Inc.: how funds voted at the meeting of 3 Jun 2026

Ticker
KLRS
Meeting
Season
year to 30 June 2026
Filers reporting
53
Ballot items
4

53 filers on Form N-PX reported votes at the Kalaris Therapeutics, Inc. meeting of 3 Jun 2026. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    3 nominees. 63.6% of the reported votes are for. 6 filers withheld from or voted against at least one nominee.

    60 vote records from 12 filers. 5 of the 12 filers that marked the item voted against management.

    • Positions of 8 fund families
    • For 4
    • Abstain or withhold 4
    • Against management 4
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    69 vote records from 53 filers. 5 of the 45 filers that marked the item voted against management. 8 filers gave no management mark.

    • Positions of 15 fund families
    • For 15
  3. Item 3: Frequency of the say-on-pay vote

    One year: 40 filers. Three years: 3 filers. Not applicable: 2 filers. 1.0: 1 filer.

    68 vote records from 51 filers. 3 of the 44 filers that marked the item voted against management. 7 filers gave no management mark.

    • Positions of 15 fund families
    • Split or no vote 15
    • Against management 3
  4. Item 4: Audit-related items (auditor ratification)

    20 vote records from 12 filers. 0 of the 12 filers that marked the item voted against management.

    • Positions of 8 fund families
    • For 8

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Kalaris Therapeutics, Inc., meeting of 3 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Pay-vote frequency4. Auditor
BlackRock and iSharesForSplitFor
BNY MellonForSplitNo report
DimensionalForSplit, against managementNo report
EquitableForSplitFor
Federated HermesForSplitNo report
FidelityForSplitFor
Goldman SachsForSplitFor
Guggenheim and RydexForSplitFor
Jackson National fundsForSplit, against managementFor
John Hancock and ManulifeForSplitNo report
Lincoln FinancialForSplit, against managementFor
Northern Trust and FlexSharesForSplitNo report
State Street and SPDRForSplitNo report
T. Rowe PriceForSplitNo report
VanguardForSplitFor

Questions

How many filers reported votes at the Kalaris Therapeutics, Inc. meeting?
53 Form N-PX filers reported votes at the meeting of 3 Jun 2026. On say-on-pay, 5 of 45 filers that marked the item voted against management (11.1%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Kalaris Therapeutics, Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Kalaris Therapeutics, Inc. with a meeting date within three days of 3 Jun 2026. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .